Consider these key pieces of clinical information when adding Ranexa® to a patient's treatment plan.
Based on a post-hoc analysis of patients in the CARISA trial
Ranexa does not affect the rate-pressure product, a measure of myocardial work, at maximal exercise
BB=beta-blocker; bpm=beats per minute; CCB=calcium channel blocker; SE=standard error.Please see full CARISA trial design, including baseline characteristics.
Exercise testing confirmed continuous effects throughout the 12-hour dosing interval maintained at weeks 2, 6, and 12 of treatment.3
Change in treadmill exercise duration from baseline at trough ranolazine levels over time3
Ranexa should be initiated at 500 mg BID and increased to 1000 mg BID as needed, based on clinical symptoms.1
For patients receiving long-acting nitrate therapy, guidelines recommend a nitrate-free interval of at least 10 to 14 hours every 24 hours to prevent nitrate tolerance.5
Ranexa is contraindicated in patients1:
Limit the dose of Ranexa to 500 mg BID when coadministered with diltiazem, verapamil, or other moderate CYP3A inhibitors.
BID=twice a day.
Is the burden of angina under-recognized in your patients? Encourage open communication to help accurately assess the presence and frequency of your patients’ angina.
Learn more about prevalence, symptom reporting, and recurrence post-PCI.Understand the Challenges
Learn about safety data from the Ranexa clinical trials, including use in special populations.Review Safety & Tolerability
Ranexa Connect™ is a financial assistance resource for patients with a Ranexa prescription.
Ranexa Connect is pleased to announce iAssist, a program to help get your patients started on Ranexa faster. The program offers online patient enrollment, electronic signatures, as well as real-time pharmacy benefit check and eligibility for financial assistance.Get Started Now